The European Commission has released a new set of proposals to replace the ePrivacy Directive (Directive 2002/58/EC). The proposals seek to update the directive which deals with privacy protection and users of electronic communication services. The proposals are aimed at increasing trust in the digital single market and aligning ePrivacy laws with the more stringent rules under the General Data Protection Regulation (GDPR) going into effect May 2018. The Directive is designed to harmonise the privacy regime so all individuals and businesses in the EU are subject to a unanimous high level of protection. What to expect There are…
The US has always been a hotbed of venture capital investment. In 2015, the National Venture Capital Association reported $58.8 billion was invested in the US, with VCs investing 5.4 times more money in the US than in Europe. According to Tech.eu’s recent funding report, European technology startups raised around €16.2 billion in 2016. Despite the fact that those numbers don’t touch the US investment numbers, we still see increased interest in UK and European start-ups from US investors. The deep pockets of Silicon Valley VCs have filled the dreams of entrepreneurs around the world, but diving into a US funding round without…
As discussed in The New World Order of Innovative Financing, investors are increasingly opting to invest into companies in advance of formal funding rounds (including seed rounds). In the UK, these investments are usually made through convertible loan notes or advanced subscription agreements (known as ASAs). In the US similar instruments like Simple Agreement for Future Equity (SAFE) by Y Combinator and Keep It Simple Security (KISS) from 500 Startups have seen increased usage. In this post, we’re look at the advantages and disadvantages of these instruments from the both the investor and company perspectives. We’ll also look at what…
In May 2018, the UK will implement the General Data Protection Regulation (GDPR) which was created to strengthen and unify data protection for individuals in the European Union. The Information Commissioner’s Office (ICO) is responsible for the Data Protection Act 1998 and Freedom of Information in the UK. The ICO recommends 12 steps businesses should take before May 2018 in order to help businesses prepare for compliance with the GDPR in 2018. Awareness: Inform all decision makers in your organisation that the law is changing and the GDPR will be effective in May 2018. Information audit: Document where all personal data is derived…
In early December, Techcrunch Disrupt London came to town. The event hosts Startup Battlefield which gathers early stage startups together on one stage to compete for the Disrupt Cup and a cash prize. As expected, the agenda was jam-packed with a wide-range topics from Brexit and walking robot dogs to flying cars and the continued disruption and innovation of Fintech. On the VC front On the venture capital front, Niklas Zennström, Atomico said that early stage Seed and Series A investments in Europe are now on par with the US, both in terms of amount of capital invested and number of companies….
According to data from London & Partners, UK tech companies raised more than $2.1 billion in the first nine months of 2015. In January 2016, London & Partners released new data indicating that since 2010, UK technology companies have collectively raised almost $10 billion. Inc Magazine published an article about the 10 growing VC trends to look for in 2016. Among them was early and seed stage funding. Whether it’s via a crowd sourced platform, seed investor or super angel, the options for early stage capital isn’t slowing down. This type of funding increasingly takes the form of quick, efficient…
According to The Macro, the ecosystem for seed or early financing is far more complex now than it was just five years ago. From super angels or micro VCs to VC firms themselves with an emphasis on seed funding, the landscape has multiple layers inside the seed funding market. Even the size of seeds has changed. The average size of a seed round on the rise anywhere from €200,000 to €6 million (what we call a super-sized seed). There’s a lot of advice out there too. Philipp Moehring, Head of Europe for AngelList, has some tips for raising a seed round without…
We’re pleased to be advisors to InMotion, the independent venture from Jaguar Land Rover. InMotion plans to transform the experience of personal travel and deliver greater freedom, choice and well-being in movement. In other words, smart transportation. Smart Transportation Hackathon On November 3, 2016 in London, InMotion is having it’s first hackathon. The hackathon is focused on transforming the future of transportation. During the day, from 5:30 to 11:30 pm, hackers will have a chance to solve a technical challenge that can be utilised by the wider community. This gives them a chance to be a part of solving real customer mobility problems….
Looking back to our last post in the Ins and Outs series on Confidentiality, you’ll see there’s an obvious disconnect and therefore potential conflict in relation to publication rights between a sponsor and the principal investigator (PI)/institution. Onerous restrictions on publication rights could be counterproductive and unlikely to be accepted by the institution and PI. For a start, it could potentially sour the goodwill and alliance established between the institution, PI and sponsor prior to commencing the clinical trial. Further, sponsors understand that for many institutions and PIs, in addition to facilitating the development of new medicines, conducting clinical trials has the allure…
In Life Science news, Akarna Therapeutics Ltd. was acquired by Allergan plc (NYSE: AGN) for an upfront cash payment of $50 million. JAG Shaw Baker acted on behalf of New Science Ventures LLC, a New York venture capital fund that invests in novel scientific approaches. New Science Ventures was one of the selling shareholders alongside Third Point Ventures and Forbion Capital Partners. Akarna Therapeutics is a UK company with offices in Cambridge, UK and San Diego, California. Akarna Therapeutic’s lead product candidate (AKN-083) is considered an effective and novel treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. An M&A…
Welcome to the JAG Shaw Baker blog. This is the place where we talk about clients, current news affecting the start-up community, trends in life sciences, digital technology and clean tech markets and even some opinions on legal matters affecting high-growth companies today. We welcome your comments!
Get in touch
If you would like any information on JAG Shaw Baker, please email our marketing department: email@example.com
London / JAG Shaw Baker / Berners House / 47-48 Berners Street / London / W1T 3NF
Edinburgh / JAG Shaw Baker / 14-18 Hill Street / Edinburgh / EH2 3JZ
Cambridge / JAG Shaw Baker / CB1 Business Centre / 20 Station Road / Cambridge / CB1 2JD
A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information
A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree.
We use the following cookies:
• Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page.
• Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB.
The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime.
You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website.